Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Monday, November 23, 2009, 7:33PM AEST - The Australian Stockmarket is closed.
To create a watchlist or portfolio of shares,
Register
FINANCE HOME PAGE
INVESTING
FINANCE NEWS
PERSONAL FINANCE
SMALL BUSINESS
Enter symbol(s):
Symbol Lookup
|
Exchanges
Search News:
Aradigm Corp. (ARDM.OB)
On Nov 21:
0.16 USD
0.00 (0.00%)
MORE ON ARDM.OB
Quotes
Summary
Options
Historical Prices
Charts
Basic Chart
Technical Chart
Technical Analysis
Detailed Data
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheet
Cash Flow
ARADIGM CORP
(OTC BB:ARDM.OB) Delayed quote data
Last Trade:
0.16 USD
Trade Time:
Nov 21
Change:
0.00 (0.00%)
Prev Close:
0.16
Open:
N/A
Bid:
N/A
Ask:
N/A
1y Target Est:
2.25
Day's Range:
N/A - N/A
52wk Range:
0.07 - 0.37
Volume:
0
Avg Vol
(3m)
:
304,141
Market Cap:
16.38M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-0.19
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Add ARDM.OB to Portfolio
Download Data
HEADLINES
Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
Business Wire
(Mon, Nov 16)
ARADIGM CORP Financials
EDGAR Online Financials
(Sat, Nov 14)
New Star Analyst Rankings for ARADIGM CORP
StarMine
(Mon, Nov 9)
ARADIGM CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online
(Sat, Nov 7)
Aradigm Announces Third Quarter 2009 Financial Results
Business Wire
(Thu, Nov 5)
Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
Business Wire
(Thu, Oct 22)
Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin
Business Wire
(Mon, Sep 14)
Emerging Stock Report Initiates Independent Research Coverage On Aradigm Corp.
GlobeNewswire
(Wed, Sep 9)
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online
(Fri, Aug 7)
ARADIGM CORP Files SEC form 10-Q, Quarterly Report
EDGAR Online
(Fri, Aug 7)
More Headlines for ARDM.OB...
ANALYST
EPS Est (next year)
(Dec-09)
:
-0.14
EPS Est (in 2 years)
(Dec-10)
:
N/A
Avg Rec (current)*:
1.0
PEG Ratio:
N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Australia
New Zealand
US
----------------
Argentina
Austria
Brazil
Canada - Toronto
Canada - Vancouver
China - Shanghai
China - Shenzhen
Denmark
France
Germany XETRA
Germany - Berlin
Hong Kong
India - Bombay
India - National
Indonesia
Israel
Italy
Malaysia
Mexico
Netherlands
Norway
Singapore
South Korea - Korea
South Korea - KOSDAQ
Spain
Sweden
Switzerland
Taiwan OTC
Taiwan
Thailand
United Kingdom
Symbol Lookup
Latest News
7 Indices